文献速递神经肿瘤

胶质瘤的当代预后特征与精细风险分层:4400例肿瘤分析

Contemporary prognostic signatures and refined risk stratification of gliomas: An analysis of 4400 tumors.
PubMed 文献 · Neuro Oncol · 2025-01-01

研究整合TCGA、GENIE及Dana-Farber/Brigham队列共4400例胶质瘤,结合回顾性临床、组织学与分子数据及前瞻性生存评估,按现代分子标准重新分类,27.2%的肿瘤原组织学诊断被更新;非TCGA患者总生存优于TCGA患者,并构建基于年龄、分子特征与治疗的总生存列线图。

要点

  • 4400例胶质瘤中,分子分类使27.2%的肿瘤从原组织学诊断被更新。
  • 非TCGA患者总生存较TCGA患者显著改善,胶质母细胞瘤、IDH1/2突变星形细胞瘤、少突胶质细胞瘤分别延长26.7%、55.6%、127.8%(均P<.01)。
  • 基于年龄、分子特征与治疗的列线图可评估总生存概率。

核心结论

  • 应用现代分子标准刻画了胶质瘤各亚型的基因组多样性,识别出临床可用的预后特征,并提供当代患者生存更新作为后续研究参考。

研究设计与样本

  • 从TCGA、GENIE及Dana-Farber Cancer Institute/Brigham and Women's Hospital组建组织病理学诊断的胶质瘤患者队列,整合回顾性临床、组织学与分子数据及前瞻性生存评估。

主要发现

  • 共识别4400例胶质瘤:2195例胶质母细胞瘤、1198例IDH1/2突变星形细胞瘤、531例少突胶质细胞瘤、271例其他IDH1/2野生型胶质瘤、205例儿童型胶质瘤。
  • 分子分类使27.2%的胶质瘤从原组织病理学诊断被更新。
  • 非TCGA患者总生存较TCGA患者显著改善:胶质母细胞瘤延长26.7%、IDH1/2突变星形细胞瘤延长55.6%、少突胶质细胞瘤延长127.8%(均P<.01)。
  • 胶质母细胞瘤中NF1改变与21q缺失、IDH1/2突变星形细胞瘤中EGFR扩增与22q缺失等预后特征被刻画。
  • 基于患者年龄、肿瘤分子特征与所接受治疗生成列线图以评估总生存概率。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: With the significant shift in the classification, risk stratification, and standards of care for gliomas, we sought to understand how the overall survival of patients with these tumors is impacted by molecular features, clinical metrics, and treatment received. METHODS: We assembled a cohort of patients with histopathologically diagnosed glioma from The Cancer Genome Atlas (TCGA), Project Genomics Evidence Neoplasia Information Exchange, and Dana-Farber Cancer Institute/Brigham and Women's Hospital. This incorporated retrospective clinical, histological, and molecular data alongside a prospective assessment of patient survival. RESULTS: Of 4400 gliomas were identified: 2195 glioblastomas, 1198 IDH1/2-mutant astrocytomas, 531 oligodendrogliomas, 271 other IDH1/2-wild-type gliomas, and 205 pediatric-type glioma. Molecular classification updated 27.2% of gliomas from their original histopathologic diagnosis. Examining the distribution of molecular alterations across glioma subtypes revealed mutually exclusive alterations within tumorigenic pathways. Non-TCGA patients had significantly improved overall survival compared to TCGA patients, with 26.7%, 55.6%, and 127.8% longer survival for glioblastoma, IDH1/2-mutant astrocytoma, and oligodendroglioma, respectively (all P < .01). Several prognostic features were characterized, including NF1 alteration and 21q loss in glioblastoma, and EGFR amplification and 22q loss in IDH1/2-mutant astrocytoma. Leveraging the size of this cohort, nomograms were generated to assess the probability of overall survival based on patient age, the molecular features of a tumor, and the treatment received. CONCLUSIONS: By applying modern molecular criteria, we characterize the genomic diversity across glioma subtypes, identify clinically applicable prognostic features, and provide a contemporary update on patient survival to serve as a reference for ongoing investigations.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Ghosh HS, Patel RV, Woodward E, et al. Contemporary prognostic signatures and refined risk stratification of gliomas: An analysis of 4400 tumors. Neuro Oncol. 2025. PMID: 39164213. doi:10.1093/neuonc/noae164

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。